Archive for the ‘Vaccine’ Category

Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine

Comments expressed during tour of South African clinical trial site where Emergent’s TB vaccine candidate is expected to complete enrollment in April for its Phase IIb efficacy study
ROCKVILLE, Md., Feb 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that a joint delegation of Members of the European Parliament (MEPs) and [...]

March 3, 2011  Tags: , , , , , ,   Posted in: Clinical trial, Emergent BioSolutions, TB, Vaccine, fuad el-hibri  No Comments

Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians

ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]

July 13, 2010  Tags: , , , , ,   Posted in: Emergent BioSolutions, NATO, North Atlantic Treaty Organization, United States Department of Health and Human Services, Vaccine  No Comments

Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments

ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations.  The company’s international sales efforts have resulted in these sales [...]

July 7, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, El-Hibri, Emergent BioSolutions, Vaccine, fuad el-hibri  No Comments